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Botulinum neurotoxin type A (BoNT/A) is a metalloprotease that blocks synaptic transmission via the cleavage of SNAP-25
(synaptosomal-associated protein of 25 kDa). BoNT/A is successfully used in clinical neurology for the treatment of several neuromus-
cular pathologies and pain syndromes. Despite its widespread use, relatively little is known on BoNT/A intracellular trafficking in
neurons.Using the visual pathway as amodel system, herewe show that catalytically activeBoNT/A is capable of undergoing anterograde
axonal transport and transcytosis. Following BoNT/A injection into the rat eye, significant levels of BoNT/A-cleaved SNAP-25 appeared
in the retinorecipient layers of the superior colliculus (SC). Anterograde propagation of BoNT/A effects required axonal transport, ruling
out a systemic spreadof the toxin.CleavedSNAP-25waspresent inpresynaptic structuresof the tectum,but retinal terminalsweredevoid
of the immunoreactivity, indicative of transcytosis. Experiments based on sequential administration of BoNT/A and BoNT/E showed a
persistent catalytic activity of BoNT/A in tectal cells following its injection into the retina. Our findings demonstrate that catalytically
active BoNT/A is anterogradely transported from the eye to the SC and transcytosed to tectal synapses. These data are important for a
more complete understanding of the mechanisms of action of BoNT/A.
Introduction
Botulinum neurotoxins (BoNTs, seven serotypes, from A to G)
and tetanus neurotoxin (TeNT) form the clostridial neurotoxin
family and are the most potent poisons known (Johnson, 1999;
Rossetto et al., 2006). They bind with high affinity to neuronal
membranes and block neurotransmission via the specific cleav-
age of synaptic SNARE (soluble N-ethylmaleimide-sensitive fu-
sion protein attachment receptor) proteins (Schiavo et al., 2000;
Rossetto et al., 2001; Turton et al., 2002; Sudhof, 2004; Binz and
Rummel, 2009). These toxins are composed of a 100 kDa heavy
chain (H chain) and a 50 kDa light chain (L chain) linked by a
single disulfide bond. The L chain is endowed with an endopep-
tidase activity specific for members of the SNARE family (synap-
tobrevin, syntaxin and SNAP-25—synaptosomal-associated
protein of 25 kDa). In particular, BoNT/A and BoNT/E cleave
SNAP-25, removing 9 and 26 residues, respectively (Schiavo et
al., 2000). These two serotypes differ markedly in duration of
action. Intoxication by BoNT/E is short-lived (days), while the
neuroparalytic effects of BoNT/A persist for months in humans
and weeks in mice (Eleopra et al., 1998; Adler et al., 2001;
Meunier et al., 2003; Morbiato et al., 2007).
In the laboratory setting, clostridial neurotoxins are excellent
tools for studying cellular physiology and SNARE-mediated
membrane fusion. In the clinic, the long-lasting effects of
BoNT/A at peripheral nerve terminals have been exploited for the
treatment of several neuromuscular and autonomic disorders,
such as dystonia, spasticity, and hyperhidrosis (Johnson, 1999;
Davletov et al., 2005;Montecucco andMolgo, 2005; Naumann et
al., 2008; Simpson et al., 2008a,b). BoNT/A has proven very ef-
fective in the treatment of these conditions, and the range of
possible clinical applications of BoNT/A is continuously increas-
ing (Evidente and Adler, 2010). Of particular interest, the action
of BoNT/A on nociceptive neurons has prompted its use in the
management of different types of pain (Casale andTugnoli, 2008;
Pavone and Luvisetto, 2010), and this is currently an area of very
active investigation.
Despite the widespread use of BoNT/A, much remains to be
understood on the mechanisms involved in binding, sorting and
intracellular trafficking of BoNT/A in neurons. Uptake of
BoNT/A at the nerve terminal occurs via synaptic vesicle endo-
cytosis, followed by translocation of the L chain into the neuronal
cytosol and cleavage of the target substrates (Binz and Rummel,
2009). While most of BoNT/A remains at the injection site, there
is experimental evidence in animal models that this toxin can
undergo retrograde axonal transport and transcytosis, particu-
larly when high doses are used (Habermann, 1974; Wiegand et
al., 1976; Moreno-Lo´pez et al., 1997; Antonucci et al., 2008b).
Transcytosis refers to the process bywhich a ligand penetrates the
neuron at one side, followed by its movement and release at the
opposite end, with possible uptake by second-order neurons.
This cell-to-cell trafficking is important because it may allow the
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toxin to exert its actions at a distance from the injection site.Here,
we have examined anterograde trafficking and transcytosis of
BoNT/A in the rat retinotectal pathway, as this system offers
several advantages. In fact, retinal ganglion cells are amenable to
surgical manipulation in vivo, and anterograde transport can be
precisely quantified (von Bartheld et al., 2001; Caleo and Cenni,
2004; von Bartheld, 2004). We report that catalytically active
BoNT/A does undergo anterograde transport and transcytosis in
neurons.
Materials andMethods
Adult Long–Evans rats bred in our animal fa-
cility were used in this study. The animals were
kept on a 12 h light/dark cycle and had access
to food and water ad libitum. All experi-
ments were performed in accordance with the
European Community Council Directive of
November 24, 1986 (86/609/EEC) and were
approved by the Ministry of Health. A total of
90 animals were used.
BoNT/A and BoNT/E were prepared and
tested as described previously (Schiavo and
Montecucco, 1995; Costantin et al., 2005;
Caleo et al., 2007; Antonucci et al., 2008b).
Intraocular injections. BoNT/A was slowly
injected into the vitreous (1–3 nM, 0.4 l) via a
glass micropipette inserted at the ora serrata
(Caleo et al., 1999). Similarly,CTB (cholera toxin
 subunit; 1%, 2.5l; Sigma)or the axonal trans-
port blocker colchicine (10 g; Sigma) were in-
jected in some experiments (Antonucci et al.,
2008b). Colchicine was injected 16–18 h before
BoNT/A. The optic nerve was sectioned using a
retroorbital approach (Antonucci et al., 2008b).
BoNT/E and kainic acid injections. BoNT/E
and kainic acid (KA) injections into the SC
were performed by a glass micropipette con-
nected to an injector. Injections were per-
formed at the following coordinates (in mm
with respect to lambda): anteroposterior,
0.5; ML, 1; 2.8 below dura (Tropea et al.,
2003). BoNT/E (50 nM, 0.5 l) was injected
into the SC 3 d after intravitreal BoNT/A deliv-
ery in 10 rats. KA (1 nmol in 100 nl of PBS;
Sigma; Antonucci et al., 2008a) was injected 1 d
before BoNT/A (6 rats).
Immunoblotting. Immunoblotting was per-
formed as described previously (Caleo et al.,
2007; Antonucci et al., 2008b). Proteins were
extracted with lysis buffer (1% Triton X-100, 10% glycerol, 20 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 10 mM EDTA, 0.1 mM Na3VO4, 1 g/ml
leupeptin, 1g/ml aprotinin, and 1mM PMSF), and the total concentra-
tion of the samples was assessed with a protein assay kit (Bio-Rad) using
a bovine serum albumin-based standard curve. Protein extracts were
separated by electrophoresis and blotted, and filters were incubated with
primary antibodies overnight at 4°C (anti-cleaved SNAP-25, 1:500 dilu-
tion, characterized in the work of Antonucci et al., 2008b; anti-vGlut-2,
1:1000, Millipore). Blots were then reacted with HRP-conjugated sec-
Figure 1. SNAP-25 cleavage in the BoNT/A-injected retina and optic nerve.A, Experimental protocol. BoNT/A (1–3 nM, 0.4l) was injected intraocularly and proteolysis of SNAP-25was assayed
in the retinaand superior colliculus.B, Immunohistochemistry showing cleaved formof SNAP-25 (red) in the injected retina (ret ipsi BoNT/A).No specific signal is detectable in the contralateral retina
(ret contra BoNT/A). ONL, Outer nuclear layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. Scale bar, 25 m. C, Cleaved SNAP-25 immunoreactivity (red) in a
longitudinal section from a crushed optic nerve ipsilateral to BoNT/A injection. Staining was performed 24 h after the crush. Note cleaved SNAP-25-positive profiles on the proximal side (left). The
site of crush is indicated by an arrow. Scale bar, 100m.
Figure 2. Anterograde propagation of BoNT/A effects along the visual pathway. A, Immunostaining demonstrating cleaved
SNAP-25 labeling in the SC contralateral (Contra) to the injected retina. Note labeling in the superficial, retinorecipient layers of the
SC. No signal is detectable in the SC ipsilateral (Ipsi) to the injected retina. Scale bar, 500 m. B, Immunoblotting for cleaved
SNAP-25 (cl. SNAP-25) on protein extracts from the injected retina (ret) and the contralateral (C) and ipsilateral (I) SC. Note
SNAP-25 cleavage in the SC contralateral to the injected retina. Tenmicrograms of proteinwere loaded for retinal samples, 100g
for SC samples. -Tubulin, internal standard. C–E, Immunostaining for cleaved SNAP-25 (red) in the pretectal area (C), dorsal
lateral geniculate nucleus (D) and visual cortex (E) contralateral to the BoNT/A-injected eye, 3 d after operation. Scale bar, 10m.
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ondary antibodies (Jackson ImmunoResearch) and developed by ECL
(GE Healthcare). Filters were also probed with anti-tubulin antibody
(monoclonal, 1:15,000 dilution, Sigma; polyclonal, 1:10,000 dilution,
Abcam), which serves as an internal standard for protein quantification.
Total proteins loaded were 10 g for retinal extracts, 10 g for collicular
extracts to detect vGlut-2, 100 g for collicular extracts to detect cleaved
SNAP-25. In Western blot experiments for Figures 6 and 8 (see below),
we loaded 20g of total proteins per lane.Quantification ofWestern blot
experiments was performed as described previously (Caleo et al., 2007;
Antonucci et al., 2008b; Mainardi et al., 2010).
Immunohistochemistry.Animals were deeply anesthetized with chloral
hydrate and perfused through the heart with freshly prepared 4% para-
formaldehyde in 0.1 M phosphate buffer, pH 7.4. Tissues were dissected
and postfixed for 2 h at 4°C. Brain sections (40 m thick) were cut with
a freezingmicrotome. Eye cups and optic nerves were embedded in OCT
compound (LeicaMicrosystems). Retinal vertical sections (20m thick)
and longitudinal nerve sections (16 m thick; Caleo et al., 2000; Man-
dolesi et al., 2005)were cut with a cryostat. For immunostaining, sections
were blocked with 10% normal horse serum in PBS containing 0.25%
Triton X-100 and then incubated overnight at room temperature with
the anti-cleaved SNAP-25 antibody (1:500 dilution). On the following
day, sections were incubated with Alexa Fluor 568-conjugated secondary
antibody (1:500; Invitrogen) for 2 h at room temperature. Sections were
then washed in PBS and mounted with antifading agent (Vectashield;
Vector Laboratories). In double-labeling for cleaved SNAP-25 and pre-
synaptic markers, collicular sections were incubated as described previ-
ously (see above), with anti-cleaved SNAP-25 and, respectively, mouse
monoclonal anti-synapsin (1:200, Synaptic Systems), mouse monoclonal
anti-vGlut-1 (1:100, Synaptic Systems), guinea pig anti-vGAT (anti-
vesicular GABA transporter; 1:300, Synaptic Systems), mouse monoclonal
anti-vGlut-2 (1:1000,Millipore). In the experiments in which CTB (Sigma)
was injected, double-labeling between CTB and, respectively, cleaved
SNAP-25 and intact SNAP-25 weremade by incubating tectal sections with
anti-CTB (1:4000, Merck KGaA) and anti-cleaved SNAP-25 or anti-intact
SNAP-25 (1:1000, SternbergerMonoclonals). For anti-intact SNAP-25, sec-
tions were postfixed in methanol for 5 min at20°C before the immuno-
histochemical process.NeuN immunohistochemistrywas performedwith a
mousemonoclonal antibody (1: 500,Millipore).Glialmarkerswere revealed
with mouse monoclonal anti-glial fibrillary acidic protein (1:500, Sigma)
and mouse monoclonal OX-42 antibody (1:500; BD Biosciences PharMin-
gen). Bound primary antibodies were revealed by Alexa Fluor-conjugated
secondaries (Invitrogen).
Immunohistochemical quantification of cleaved SNAP-25 and vGlut-2.
Confocal images were collected with a Leica confocal microscope using a
63 oil-immersion lens. An initial analysis on stained sections was per-
formed to establish settings for laser intensity, gain, offset and pinhole
size. Care was taken to avoid saturation at either end of the pixel intensity
range (0–255). Confocal settings were then held constant through the
study. For each coronal section, two representative fields were acquired
using the same settings in the control and denervated SC. All fields were
located in the stratum griseum superficiale. Stacks of images were col-
lected at the top face of the tissue section and the image within each stack
with the highest average pixel intensity was selected for the quantitative
analysis of immunoreactivity. Quantification was performed withMeta-
Morph software (Molecular Devices). The area occupied by cleaved
SNAP-25- and vGlut-2-positive pixels was calculated for each image by
applying a threshold that removes background levels of fluorescence, and
calculating the percentage of positive pixels in the field (Tropea et al.,
2003; Caleo et al., 2007, 2009).
Colocalization analysis. Colocalization was performed essentially as
described by Tropea et al. (2003) usingMetaMorph software (Molecular
Devices). Two stacks of optical sections separated by 1mwere collected
on a confocal microscope (Leica). One stack contained images of cleaved
SNAP-25, while the other contained images of a synaptic terminal label
(synapsin, vGlut-1 and -2, vGAT, CTB). All images were collected
through a 63 objective. Image size was 512 512 pixels, resulting in a
pixel size of 0.08m. The optical section with highest pixel intensity was
selected for colocalization analysis. Images from both channels were
thresholded to remove background levels of fluorescence and retain only
the brightest pixels. Thus, each image was binarized so that pixels above
threshold were set to 1 and pixels with background fluorescence were set
to 0. We then determined the percentage of double-labeled pixels in the
neuropil. The analysis was perfomed on 8 different confocal stacks per
animal. To estimate the amount of colocalization expected based on
random overlap of the two labels, we performed the same colocalization
analysis after rotation by 90 degrees of the cleaved SNAP-25 image
(“shuffled” condition). A synaptic marker was considered to be colocal-
izedwith cleaved SNAP-25when there was a significant difference (t test)
Figure 3. Propagation of BoNT/A effects requires axonal transport. A, Immunoblotting
showing cleaved SNAP-25 (cl. SNAP-25) levels in the retina and in the superior colliculi (C,
contralateral to the injection; I, ipsilateral to the injection) of one animal injected intraocularly
with BoNT/A (left lanes) and one animal subjected to colchicine injection (10g) 16 h before
BoNT/A (right lanes). Note the loss of signal for cleaved SNAP-25 in the contralateral SC of the
animal treated with colchicine (BoNT/A Colch).-Tubulin, internal standard.B, Quantifica-
tionof cleavedSNAP-25 levels. Levels of cleavedSNAP-25 in the superior colliculi arenormalized
to levels of expression in the corresponding retinal samples. In animals treatedwith colchicine,
expression of cleaved SNAP-25 in the superior colliculus contralateral to injected retina is virtu-
ally abolished. Data are mean SE. BoNT/A, n 4, BoNT/A colchicine, n 5. *p 0.05.
Figure 4. Localization of cleaved SNAP-25 in the tectum. A, B, Animals were injected intra-
ocularlywith BoNT/A and killed at 3 d. Immunostaining in SC sections for cleaved SNAP-25 (red)
and the synaptic vesicle marker synapsin (green; B). C, D, Animals were injected intraocularly
with BoNT/A and killed at 15 d. Immunostaining in SC sections for cleaved SNAP-25 (red) and
the glial markers GFAP (green in C) and OX-42 antibody (green in D). Scale bar, 10m.
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in the percentage of double-positive pixels between the normal and shuf-
fled condition.
Results
Anterograde propagation of BoNT/A effects in the
visual system
To examine anterograde propagation of BoNT/A effects in the
visual system, BoNT/A (1–3 nM, 0.4 l) was injected into the
vitreous humor of adult rats (Fig. 1A). This dose of toxin was
chosen based on previous studies of central and peripheral ad-
ministration of BoNT/A in rats (Franchi, 2002; Franchi and
Veronesi, 2004; Antonucci et al., 2008b). Three days later, retinal
and tectal sections were immunostained with an antibody spe-
cific for BoNT/A-truncated SNAP-25. Previous experiments
have demonstrated that this antibody recognizes specifically the
cleaved form of SNAP-25 and not the whole protein (Antonucci et
al., 2008b; Matak et al., 2011). In the injected retina, strong staining
was found in the inner plexiform layer; cell bodies of bipolar cells in
the inner nuclear layer were also stained (Fig. 1B, left). A fainter
labeling appeared in cell bodies of RGCs and in the optic nerve fiber
layer (Fig. 1B, left). To determine whether BoNT/A-truncated
SNAP-25 is detectable inRGCaxons,we injectedBoNT/A intraocu-
larly and we crushed the optic nerve to allow accumulation of the
cleavedproduct. Labeled fiberswere clearly evidenton the sideprox-
imal to the crush 24 h after surgery, indicating presence of BoNT/A-
altered SNAP-25 within retinal axons (Fig. 1C). No specific staining
was found in the contralateral, uninjected
optic nerves and retinas (Fig. 1B, right).
Examination of tectal sections revealed
consistent labeling of the retinorecipient
layers of the SC contralateral to the in-
jected eye (n  16 BoNT/A-injected rats;
Fig. 2A). Labeling was evident 3 d after
injection and became particularly promi-
nent at 15 d. Staining for cleaved SNAP-25
was typically stronger in the medial part of
the SC, topographically corresponding to
the injection site in the ventral retina. Label-
ing was virtually undetectable in the ipsilat-
eral SC (Fig. 2A, left). Thus, injection of
BoNT/A into theeye leads to theappearance
of BoNT/A-truncated SNAP-25 in the con-
tralateral tectum. This is consistent with the
fact that in the rat,97%of the RGCs proj-
ect contralaterally (Cowey andPerry, 1979).
Western blotting experiments on reti-
nal and tectal tissue extracts provided
further evidence for anterograde propaga-
tion of BoNT/A effects. We found robust
SNAP-25 cleavage in the injected retina; a
smaller, but significant, level of BoNT/A-
cleaved SNAP-25 was detected in the con-
tralateral (but not ipsilateral) SC (Fig.
2B). These data clearly indicate that pro-
teolysis of SNAP-25 appears to propagate
anterogradely from the eye in the adult
retinotectal system following BoNT/A in-
jection into the eye.
Labeling for BoNT/A-altered SNAP-25
also appeared in other retinorecipient nu-
clei such as the lateral geniculate nucleus
(Fig. 2D) and pretectal area (Fig. 2C) 3–15
d after injection. In the deep layers of pri-
mary visual cortex contralateral to the in-
jection, we found stained profiles with varicosities, likely axons
en passant (Fig. 2E). This might reflect transsynaptic labeling of
thalamocortical, corticogeniculate or corticotectal axons, as pre-
viously described for tetanus neurotoxin (Manning et al., 1990).
Anterograde propagation of BoNT/A effects is
microtubule dependent
We next examined whether anterograde propagation of BoNT/A
effects requires axonal transport. To block microtubule-dependent
transport, we used intraocular injections of the depolymerizing
agent colchicine (10 g). This dose of colchicine was previously
found to effectively prevent axonal transport along the rat optic
nerve (Caleo et al., 2000, 2003; Antonucci et al., 2008b). Injection
of colchicine blocked the anterograde propagation of BoNT/A
effects from the retina to the contralateral SC (BoNT/A, n  4,
BoNT/A colchicine, n 5; Fig. 3). The selective appearance of
BoNT/A-truncated SNAP-25 in the SC contralateral to the in-
jected retina, and the blockade of this anterograde transfer by
colchicine strongly argue against a systemic spread of toxin effects
(via blood or CSF).
Expression of BoNT/A-truncated SNAP-25 in the tectum
remains unaltered despite degeneration of RGC fibers
We next investigated the localization of BoNT/A-truncated
SNAP-25 in the optic tectum. Staining was prominent in the
Figure 5. Colocalization of cleaved SNAP-25 with vGlut-1- and vGAT-positive terminals. A–C, Animals were injected intraocu-
larly with BoNT/A and killed at 3 d. Immunostaining in SC sections for cleaved SNAP-25 (red) and presynaptic markers (green: A,
vGlut-1;B, vGAT;C, vGlut-2). Note that cleavedSNAP-25displays anevident colocalizationwith vGlut-1 andvGAT (A,B), but it does
not colocalize with vGlut-2 (C), specific for RGC terminals. D, E, Animals were injected intraocularly with an anterograde tracer
(CTB) to label RGC fibers. A subset of animals were injected 1 d later with BoNT/A and killed after another 3 d. Note the lack of
colocalization between CTB (green) and cleaved SNAP-25 (red) in D. In contrast, there is clear colocalization between CTB (green)
and the intact form of SNAP-25 (red) in E. Scale bar, 10m.
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superficial gray of the SC, but sparse in the underlying optic nerve
fiber layer (stratum opticum). Using confocal analysis at high
magnification, cleaved SNAP-25 was found associated with
puncta and processes in the neuropil surrounding tectal cells
(Fig. 4A). To determine whether cleaved SNAP-25-positive pro-
files correspond to synaptic terminals, we performed double-
label immunofluorescence for BoNT/A-altered SNAP-25 and the
synaptic vesicle marker synapsin. The quantitative analysis (Sil-
ver and Stryker, 2000; Tropea et al., 2003) demonstrated a very
significant colocalization of cleaved SNAP-25 and synapsin im-
munoreactivity (Fig. 4B). On average, 26.5 0.5% (SEM) of the
pixels in the neuropil were double-stained for BoNT/A-altered
SNAP-25 and synapsin. Confocal analysis showed no colocaliza-
tion with markers of glial cells such as GFAP (a marker of astro-
cytes; Fig. 4C) andOX-42 (an antibody that recognizesmicroglia;
Fig. 4D).
To gainmore insight into the type of nerve terminals contain-
ing truncated SNAP-25, we performed double-label immuno-
staining formarkers of excitatory (vGlut-1 and -2) and inhibitory
synapses (vGAT). In the rat SC, vGlut-2 is specifically expressed
by terminals of RGCs (Fujiyama et al., 2003; Caleo et al., 2009).
We found that cleaved SNAP-25 displayed significant colocaliza-
tion with vGlut-1 and vGAT (10.3  0.3% and 14.8  0.6% of
double-labeled neuropil pixels, respectively, a percentage signif-
icantly different from random colocalization of the two labels, t
test, p 0.001, Fig. 5A,B), while there was no colocalization with
the retinal terminal marker vGlut-2 (6.4  0.4% of double-
labeled neuropil pixels, a percentage not significantly different
from random colocalization of the two labels, t test, p 0.05; Fig.
5C). Surprised by this initial analysis, we performed amore thor-
ough set of colocalization experiments, in whichmassive labeling
of RGC terminals was achieved by intraocular injection of an
anterograde tracer (CTB; n  4 rats). This resulted in robust
staining of retinal fibers in the SC. However, confocal analysis of
CTB- and cleaved SNAP-25-positive pixels (Fig. 5D) revealed no
significant colocalization of the two markers (5.1 0.7% of pix-
els in the neuropil, no significantly different from random; t test,
p  0.23; Fig. 5D). Since SNAP-25 is abundantly expressed in
RGCs, we used antibodies to intact SNAP-25 as a positive control
for our colocalization analysis (Fig. 5E). We found a very signif-
icant colocalization when staining for CTB and the intact form of
SNAP-25was combined (30.2 1.3%of double-labeled pixels in
the neuropil).
These immunostaining data suggest that cleaved SNAP-25 is
not present within RGC terminals, but a lack of colocalization
can be caused by several technical factors, including incomplete
penetration of the antibodies, different subcellular localization of
CTB/vGlut-2 and truncated SNAP-25, and poor resolution of
synaptic puncta by confocal microscopy. To explore more di-
rectly whether cleaved SNAP-25 is present in RGC fibers, we took
advantage of the fact that cleaved SNAP-25 associated with reti-
nal terminals would be rapidly lost after section of the optic
nerve, due toWallerian degeneration of transected fibers. There-
fore, we injected unilaterally BoNT/A into the vitreous in a group
of rats (n 11), and allowed 3 d for anterograde transport to the
SC, and then we cut the optic nerve corresponding to the injected
eye in a subset of the animals (n  5). The remaining animals
(n 6) were left unoperated. We allowed another 7 d for Walle-
rian degeneration of transected RGC fibers and then performed
immunoblotting for cleaved SNAP-25 in tectal protein extracts
(contralateral to the injected retina) in control and optic nerve-
sectioned rats. We found that BoNT/A-truncated SNAP-25 was
not decreased in the denervated tectum (control vs denervated, t
test, p 0.26; Fig. 6A,B). Levels of BoNT/A-truncated SNAP-25
in the injected retina were similar between groups (t test, p 
0.73). Conversely, expression of vGlut-2 (marker of retinal ter-
minals in the tectum) was consistently dampened in the deaffer-
ented SC, consistent with the effects of optic nerve section (Fig.
6C,D; t test, p 0.05).
In a second protocol, we used bilateral, intravitreal injections
of BoNT/A, followed by section of the left optic nerve 3 d later
and immunohistochemistry for cleaved SNAP-25 at 10 d (n 6
rats). This protocol allows one to compare levels of BoNT/A-
truncated SNAP-25 in the denervated and control SC of the same
animal. We found that staining for cleaved SNAP-25 was not
abolished in the deafferented tectum (Fig. 7A).Quantitative anal-
ysis of the immunostaining revealed nodifferences between levels
of BoNT/A-truncated SNAP-25 in the SC contralateral and ipsi-
lateral to optic nerve section (Fig. 7B; control vs denervated,
paired t test, p 0.38). Importantly, quantification of the retinal
fiber marker vGlut-2 indicated a very robust decrease of the im-
munostaining (Fig. 7C,D; control vs denervated, paired t test, p
0.001), demonstrating that optic nerve section effectively re-
moves most of retinal terminals from the contralateral SC. The
immunohistochemical decrease of vGlut-2 following optic nerve
section was quantitatively greater than that observed byWestern
blot (Fig. 6B), likely because quantification of the immunostain-
ing could be restricted to the retinorecipient superficial gray of
the SC, while surgical dissection of the colliculi for immunoblot-
ting inevitably leads to pickup of tissue from nonvisual deep lay-
ers of the SC (such as the intermediate gray layer), in which
vGlut-2 is not decreased. In summary, these sets of experiments
demonstrate that expression of BoNT/A-truncated SNAP-25 in
the tectum remains unaltered despite degeneration of RGC fi-
Figure 6. Persistence of cleaved SNAP-25 in the tectum of animals with optic nerve section.
Animalswere injected intraocularlywith BoNT/A. After 3 d, a group of animalswas subjected to
optic nerve section (ON cut,n5),while the remaining ratswere left unoperated (CTR,n6).
After another 7 d, tissues were dissected and Western blot was performed. A, B, Immunoblot-
ting for cleaved SNAP-25 on protein extracts from the SC contralateral to BoNT/A injection.
Quantification demonstrated that expression of cleaved SNAP-25 in the SC does not decrease
followingRGC fiber degeneration. Levels of BoNT/A-truncatedSNAP-25arenormalized to those
measured in animalswithout ON cut. C,D, Immunoblotting for vGlut-2 on protein extracts from
the SC contralateral to BoNT/A injection. vGlut-2 is specific for RGC terminals and is used as a
control for loss of retinal innervation. Quantification demonstrated that expression of vGlut-2 in
the SC consistently decreases following ON section. Levels of vGlut-2 are normalized to those
measured in animals without ON cut.-Tubulin, internal standard. Data are mean SE. ON
cut, n 5; CTR, n 6. *p 0.05.
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bers, indicating that structures other than retinal terminals con-
tain cleaved SNAP-25.
Active BoNT/A is anterogradely transported and transcytosed
in the retinotectal system
The lack of presence of BoNT/A-truncated SNAP-25 in RGC fibers
suggests a process of anterograde transport and transcytosis, by
which BoNT/A (and/or its cleaved substrate) is released from
RGC terminals and subsequently concentrates in other synaptic
terminals in the tectum. The localization of cleaved SNAP-25
with vGlut-1/vGAT (but not vGlut-2)-positive puncta in the tec-
tum is consistent with this scenario (Fig. 5). However, as only the
distribution of BoNT/A-cleaved SNAP-25 was assayed, it could
be argued that the cleaved substrate is transported and transcy-
tosed, rather than the toxin itself. In addition, it remained unde-
termined whether BoNT/A can be transported and transcytosed
in a catalytically active form, thus capable of long-range antero-
grade actions. To address these issues, we designed an experiment
(Fig. 8A) to test whether the catalytic activity of BoNT/A appears
in the SC following toxin injection into the retina. For this exper-
iment, we injected unilaterally BoNT/A into the vitreous of 15
rats, and five of themwere killed 3 d after injection to visualize the
expected anterograde propagation of BoNT/A effects to the tec-
tum (3 d; Fig. 8B, left lanes). In the remaining animals, we per-
formed section of the optic nerve (to
prevent further transport along the vi-
sual pathway) and BoNT/E was injected
into the tectum contralateral to BoNT/
A. BoNT/A removes the last 9 residues
from the C terminus of SNAP-25, while
BoNT/E cleaves a larger 26 residue frag-
ment from the same region of SNAP-25;
in addition, the action of BoNT/E is short-
lasting (Meunier et al., 2003; Caleo et al.,
2007), while BoNT/A catalytic activity is
known to persist for much longer. In the
animals killed 2 d after BoNT/E/optic
nerve section (3 d 2 d BoNT/E; n 5),
we found that injection of BoNT/E
strongly reduced expression of BoNT/A-
truncated SNAP-25 in the tectum (t test,
3 d vs 3 d 2 d BoNT/E, p 0.05; Fig. 8B,
middle lanes; Fig. 8C). However, the cat-
alytic activity of BoNT/A reappeared in
the SC at the completion of BoNT/E ef-
fects (23 d; t test, 3 d 2 d BoNT/E vs 3 d
 23 d BoNT/E, p 0.001; Fig. 8B, right
lanes; Fig. 8C), indicating that active
BoNT/A is present within tectal terminals
and capable of generating new truncated
substrate in the SC. If BoNT/A-cleaved
SNAP-25 was transported anterogradely,
rather than the toxin itself, the reduction
of BoNT/A-truncated SNAP-25 would
have been permanent. Conversely, levels
of BoNT/A-altered SNAP-25 in the tec-
tum 23 d after the optic nerve cut were
greater than that observed 3 d after
BoNT/A (t test, p  0.01; Fig. 8C), indi-
cating the long-term presence of the
BoNT/A metalloprotease activity within
the SC. These data allow us to conclude
that active BoNT/A is anterogradely
transported from the eye to the SC and transcytosed to tectal cells,
where it maintains catalytic activity for a relatively long duration
(23 d).
BoNT/A transfer from retinal to tectal terminals does not
necessarily require internalization by postsynaptic cells
We finally investigated in more detail the mechanisms by
which BoNT/A moves from the RGC terminals to tectal syn-
apses. This transfer could be direct (release from retinal ter-
minals and uptake by presynaptic sites in the vicinity), or
involve a step of internalization by tectal cells followed by
further release and uptake. To determine whether internaliza-
tion by postsynaptic neurons is required for anterograde
propagation of BoNT/A effects, we performed an experiment
in which tectal cells were ablated in a portion of the superficial
gray by injection of a minute amount (100 nl, 1 nmol) of the
excitotoxin KA. Injection of KA is known to lead to local
neuronal loss while sparing retinocollicular and other afferent
axons (Carpenter et al., 1986). A complete loss of immuno-
staining for the neuronal marker NeuN was found in the in-
jected area (Fig. 9A). One day after the lesion, BoNT/A was
injected intraocularly and three further days were allowed for
anterograde transport. We found that cleaved SNAP-25-
positive profiles were detectable in the tectal areas completely
Figure 7. Immunohistochemical expression of BoNT/A-truncated SNAP-25 persists following retinal fiber degeneration.
BoNT/A was injected into both eyes and after 3 d all animals were subjected to unilateral optic nerve section (ON cut). The
other side served as control (CTR). After an additional 7 d, rats were perfused and immunohistochemistry was performed.
A, C, Immunostaining for cleaved SNAP-25 (red, A) and vGlut-2 (green, C) on tectal sections. In the zoomed images (boxes)
it is possible to note that staining for cleaved SNAP-25 is similar in both sides, while staining for vGlut-2 is strongly reduced
in the side corresponding to ON section, indicating the degeneration of RGCs terminals. Scale bars: top, 100m; bottom,
10 m. B, D, Quantification of cleaved SNAP-25 (B) and vGlut-2 levels (D) on tectal sections. There is no statistically
significant difference in cleaved SNAP-25 staining between the two colliculi. Note, instead, the clear reduction of vGlut-2
staining in the colliculus contralateral to the ON section, demonstrating degeneration of RGCs terminals. Data are mean
SE. CTR side, n 6; ON cut side, n 6. ***p 0.001.
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devoid of NeuN immunoreactivity, although their density was
lower than that found in adjacent, unlesioned areas (Fig.
9B,C). Thus, tectal cells are dispensable for the anterograde
propagation of BoNT/A effects.
Discussion
The data presented in this article demonstrate anterograde traf-
ficking and transcytosis of catalytically active BoNT/A in neu-
rons. They were obtained with a very relevant model system: the
rat retinotectal pathway which allows to assay for transcytosis via
optic nerve section and use of RGC-specific markers (von Bar-
theld et al., 1996; Caleo et al., 2000, 2009; von Bartheld and Bu-
towt, 2000). In the rat, virtually all RGCs send a unidirectional
projection to the superior colliculus, with 97%of the axons cross-
ing at the chiasm and innervating the contralateral tectum
(Cowey and Perry, 1979). Cell bodies of RGCs can be easily ex-
posed to exogenous ligands by injections into the vitreous hu-
mor, and the optic nerve is amenable to surgical manipulation
(Manning et al., 1990; von Bartheld et al., 1996; Caleo et al., 2000,
2009; von Bartheld and Butowt, 2000). This model system has
been extensively used for studies of anterograde transport and
transcytosis (von Bartheld et al., 2001; Caleo and Cenni, 2004;
von Bartheld, 2004).
In this article, we have used the cleavage of the BoNT/A sub-
strate SNAP-25 as a marker for toxin action in distant sites. This
choice is justified by the fact that detection of BoNT/A itself is
technically challenging due to the very tiny amounts of injected
toxin; in addition, measuring cleavage is a more sensitive assay
for BoNT/A trafficking, as a small number of toxinmolecules can
cleave massive amounts of the substrate, thus providing a dra-
matic amplifying effect. We found significant levels of BoNT/A-
truncated SNAP-25 in the tectum after BoNT/A delivery into the
eye. The blockade of this anterograde propagation of BoNT/A
effects by coinjection of colchicine ruled out a systemic spread of
the toxin (via blood or CSF). Interestingly, cleaved SNAP-25 in
the tectum apparently accumulated in synaptic endings, but was
not associated with RGC terminals. This points to a process of
transcytosis by which BoNT/A and/or the cleaved substrate are
transferred from RGCs to tectal terminals. Here, the question
arises as to whether detection of the cleaved substrate can be
unequivocally interpreted as presence of the BoNT/A protease.
The BoNT/E injection into the tectum coupled with optic
nerve section a few days after intravitreal delivery of BoNT/A
provides compelling functional evidence that a persistent pro-
teolytic activity of BoNT/A resides in tectal synapses. In par-
ticular, tectal delivery of BoNT/E produced a consistent
reduction of BoNT/A-altered SNAP-25, that returned at high
levels at the completion of BoNT/E effects. The reappearance
of BoNT/A-truncated SNAP-25 cannot be explained by ongo-
ing anterograde transport from the eye, as the optic nerve was
severed concomitantly with BoNT/E. Rather, the return of
BoNT/A-cleaved SNAP-25 indicates persistent BoNT/A cata-
lytic activity in the superior colliculus, since there are no other
means to generate new truncated substrate in the tectum. This
proves that catalytically active BoNT/A was transferred to tec-
tal terminals during the first 3 d following intraocular admin-
istration. The demonstration of cell-to-cell transfer of active
BoNT/A is extremely relevant because it provides proof-of-
principle that this toxin can affect cellular targets that are
distant from the administration site. It will be important in
future studies to determine what are the functional conse-
quences of this distant cleavage at the level of individual syn-
aptic boutons. Previous work from our group (Antonucci et
al., 2008b) supports long-distance functional changes after
BoNT/A delivery, as shown by the fact that trans-hemispheric
propagation of BoNT/A effects in the hippocampus results in
electrophysiological consequences. Here, we choose not to
provide functional measures in the SC, because of the con-
founding effects of blockade of afferent retinal activity, that
likely impacts per se physiological parameters in the tectum.
The mechanisms and cellular compartments involved in
the anterograde axonal transport and transcytosis of BoNT/A
remain to be elucidated. Molecules that are well known to
enter a trancytosis pathway include TeNT, lectins, and trophic
factors such as brain-derived neurotrophic factor (BDNF),
neurotrophin-3 (NT-3), and glial cell line-derived neurot-
rophic factor (GDNF). Following injection into the eye of the
rat and rabbit, fragment C of TeNT undergoes anterograde
direct transport to all retinorecipient areas. From these areas,
TeNT exhibits transcytosis to neurons that project to retino-
Figure 8. Transcytosis of catalytically active BoNT/A. A, Experimental protocol. BoNT/A was
injected intraocularly. After 3 d, tectal samples were dissected from a subset of animals, while
the other animals were subjected to optic nerve section (ON cut) and BoNT/E injection into the
colliculus. Colliculi were taken either 2 or 23 d following BoNT/E injection. B, Immunoblotting
for BoNT/A-truncated SNAP-25 on protein extracts from the SC contralateral to the injected
retina. BoNT/A-truncated SNAP-25 is clearly detectable after 3 d, disappears 2 d following
BoNT/E injection (3d 2d BoNT/E), and reemerges when BoNT/E action is off, i.e.,23 d
following BoNT/E injection (3d 23d BoNT/E).-Tubulin, internal standard. C, Quantification
of the immunoblotting experiments. BoNT/A-truncated SNAP-25 shows modest levels at 3 d
(3d), decreases 2 d after collicular injection of BoNT/E (3d 2d BoNT/E), and then shows
significantly higher levels 23 d after BoNT/E (3d  23d BoNT/E). Levels of cleaved
SNAP-25 are normalized to those measured 3 d after intraocular injection. This experi-
ment demonstrates anterograde transfer and persistence of catalytically active BoNT/A.
Data are mean SE; 3d, n 5 rats; 3d 2d BoNT/E, n 5; 3d 23d BoNT/E, n 5.
*p 0.05; **p 0.01; ***p 0.001.
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recipient areas, including neurons in layers V and VI of visual
cortex (Manning et al., 1990). Certain neurotrophic factors
can also be anterogradely transported and transcytosed. For
example, in developing chick brain, NT-3 is transported in the
anterograde direction, from cell bodies to the axon terminals,
and the intact neurotrophin is released after anterograde
transport, taken up and used by second-order visual neurons
(von Bartheld et al., 1996; von Bartheld and Butowt, 2000).
BDNF travels in an anterograde direction along the rat optic
nerve and has rapid effects on retinal target neurons in the
superior colliculus and lateral geniculate nucleus of the brain
(Caleo et al., 2000, 2003). GDNF is anterogradely transported
from the cell body of sensory neurons into the spinal cord (von
Bartheld et al., 2001). Neurotrophic factors are packaged in
large dense core vesicles during anterograde axonal transport,
released via activity-dependent mechanisms, and once secreted
they may act at either presynaptic or postsynaptic sites (von Bar-
theld et al., 2001; von Bartheld, 2004). Whether BoNT/A uses a
similar pathway for anterograde trafficking remains to be inves-
tigated. The findings that the fibroblast growth factor (FGF) re-
ceptor 3 has been identified as a component of the receptor
complex for BoNT/A (Fernandez-Salas et al., 2008), and FGF is
known to travel anterogradely in the optic nerve (Ferguson and
Johnson, 1991), suggest that BoNT/A may use an anterograde
trafficking pathway shared with trophic factors. In this context, it
is known that TeNT enters a vesicular pathway shared with neu-
rotrophins and their receptors, at least during retrograde trans-
port (Deinhardt et al., 2006; Salinas et al., 2010).
Our colocalization analysis clearly indicates significant colo-
calization of cleaved SNAP-25 with synapsin-positive terminals
(specifically, with a subset of vGlut-1- and vGAT-stained termi-
nals), but no significant colocalization with the retinal markers
vGlut-2 and CTB. Importantly, persistence of cleaved SNAP-25
in the tectum after optic nerve lesion confirms expression of
BoNT/A-altered SNAP-25 in tectal, but not RGC terminals.
Thus, RGCs appear to be mostly involved in uptake, transport
and release of the active toxin, while the cleaved product accu-
mulates in other neuronal types in the tec-
tum.One question is how the toxinmoves
from the RGC terminals to the vGlut-1
and vGAT-positive synapses. By perform-
ing an excitotoxic lesion in the SC, we
have shown that internalization by tectal
cells is not necessarily required for antero-
grade propagation of BoNT/A effects.
Therefore, these data indicate that a di-
rect, presynaptic to presynaptic route is
possible (release from RGC afferents and
uptake by other synaptic terminals in the
vicinity). Such synaptic terminals may in-
clude a contingent of corticotectal, vGlut-
1-positive synapses. In addition, the
extensive colocalization between vGAT
and BoNT/A-truncated SNAP-25 hints at
BoNT/A effects in local GABAergic in-
terneurons and possibly afferent inhibi-
tory projections from the parabigeminal
nucleus. The reduced density of cleaved
SNAP-25 profiles in the neuropil after ex-
citotoxic lesions (Fig. 9) is also consistent
with uptake of BoNT/A by terminals of
local GABAergic neurons, that degenerate
after such injury.
Our data demonstrating anterograde transport and trans-
cytosis of BoNT/A may have implications for the understand-
ing of the mechanisms of action of BoNT/A in pain. Several
studies have shown that BoNT/A can be effectively used to
treat several pathological pain conditions (Aoki, 2005) and
this line of research is rapidly growing (Pavone and Luvisetto,
2010). A likely mechanism by which BoNT/A exerts antinoci-
ceptive actions is the inhibition of release of neurotransmitter
and neuropeptides (substance P, calcitonin gene-related pep-
tide) from the peripheral branch of primary sensory neurons.
However, several recent data demonstrate bilateral antinoci-
ceptive effects of BoNT/A following unilateral, peripheral ad-
ministration of the toxin (Bach-Rojecky and Lackovic´, 2009;
Favre-Guilmard et al., 2009; Bach-Rojecky et al., 2010). This
bilateral effect suggests the involvement of the CNS in the
mechanisms of action of BoNT/A. This could occur either
indirectly (through synaptic plasticity), or directly (via axonal
transport of the toxin), as suggested by the fact that the bilat-
eral effect can be prevented by peripheral administration of
colchicine (Bach-Rojecky and Lackovic´, 2009). To exert a spi-
nal effect, it is required that the toxin ascends retrogradely
along the peripheral branch of nociceptive neurons and then
penetrates the spinal cord through anterograde transport and
transcytosis (von Bartheld et al., 2001; von Bartheld, 2004).
This possibility has never been supported experimentally be-
fore, and our data indicate for the first time that BoNT/A is
indeed capable of undergoing anterograde trafficking and
transcytosis across synapses.
In summary, we have provided proof-of-principle that
BoNT/A can undergo anterograde axonal transport and transcy-
tosis in neurons. These data are important for a more complete
understanding of the mechanisms of action and trafficking of
clostridial toxins, for the future design of drug delivery vehicles
capable to be transferred specifically across synapses, and to tar-
get specific neural circuits for long-term therapeutic effects on
neuronal function.
Figure 9. Tectal cells are dispensable for the anterograde propagation of BoNT/A effects. A, NeuN immunostaining (red) in a
coronal section throughboth colliculi, 4 d after unilateral delivery of KA. Borders of the lesion are indicatedbyarrows. Scale bar, 500
m. B, C, Double-label immunohistochemistry for NeuN (red) and cleaved SNAP-25 (green). Staining was performed 3 d after
intravitreal BoNT/A. Zoomed images are taken fromamedial, unlesioned area of the SC (B) and fromwithin the damaged zone (C).
Scale bar, 10m.
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